WuXi AppTec Announces Listing of Initial Public Offering of Common Stock on Shanghai Stock...

We are pleased to announce WuXi AppTec's  listing of Initial Public Offering of common stock on the Shanghai Stock Exchange. Proceeds from the IPO will be used to build and expand...

WuXi STA Changzhou Site Passes First U.S. FDA Inspection

We are pleased to announce STA Pharmaceutical Co., Ltd., (WuXi STA), a subsidiary of WuXi AppTec, has secured Pre-Approval Inspection (PAI) for two APIs from the U.S. Food and Drug Administration for its...

WuXi STA Announces to Build a New R&D Center in Shanghai

We are pleased to announce that WuXi's subsidiary, STA Pharmaceutical Co., Ltd, has signed an investment agreement with the government of Shanghai Jinshan District to build a new R&D center. The new...

WuXi AppTec Expands Site in the United States for Drug Development Testing Services

We are pleased to announce the grand opening of WuXi AppTec's expanded Laboratory Testing Division (LTD) facility in New Jersey. The expansion will double total operation space to more than 115,000 square...

BIO 2018: Going Deep: How AI and Machine Learning Will Transform Drug Discovery

Date: Wednesday, June 6, 2018 Time: 1:45 PM–2:45 PM EST Duration: 1 hour Room: 210C, Level 2 Register here. Overview: While machine learning and artificial intelligence have had a deep impact in solving complex global problems over the...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

INNOVATION THAT MATTERS

Capricor Therapeutics Seeking New Cell Therapy for Deadly Duchenne Disease

New breakthroughs in science, such as gene and cell therapies, give medical researchers potential new pathways to develop treatments for diseases for unmet medical...